Origami Therapeutics is a preclinical-stage company developing novel protein degrader therapeutics with a proprietary drug discovery platform which holds the promise for disease modification in neurodegenerative diseases such as Huntington’s disease. We are pioneering the next generation of small molecules targeting disease-causing proteins. At Origami Therapeutics, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a preclinical-stage biopharmaceutical company focused on developing new therapeutics for neurodegenerative diseases, beginning with Huntington’s disease. Our proprietary protein degraders work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins. We have built upon groundbreaking research of our founder Beth Hoffman, a veteran drug discovery scientist who discovered transformational therapeutics for cystic fibrosis.
Something looks off?